Salmaninejad, A. et al. PD‐1/PD‐L1 pathway: basic biology and role in cancer immunotherapy. J. Cell. Physiol. 234, 16824–16837 (2019).

Article  CAS  PubMed  Google Scholar 

Neel, B. G., Gu, H. & Pao, L. The ‘Shp’ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem. Sci. 28, 284–293 (2003).

Article  CAS  PubMed  Google Scholar 

Sharpe, A. H. & Pauken, K. E. The diverse functions of the PD1 inhibitory pathway. Nat. Rev. Immunol. 18, 153–167 (2018).

Article  CAS  PubMed  Google Scholar 

Barber, D. L. et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439, 682–687 (2006).

Article  CAS  PubMed  Google Scholar 

Alkholifi, F. K. & Alsaffar, R. M. Dostarlimab an Inhibitor of PD-1/PD-L1: a new paradigm for the treatment of cancer. Medicina 58, 1572 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Li, H., Van Der Merwe, P. A. & Sivakumar, S. Biomarkers of response to PD-1 pathway blockade. Br. J. Cancer 126, 1663–1675 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jardim, D. L., Goodman, A., de Melo Gagliato, D. & Kurzrock, R. The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell 39, 154–173 (2021).

Article  CAS  PubMed  Google Scholar 

Patel, S. P. & Kurzrock, R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol. Cancer Ther. 14, 847–856 (2015).

Article  CAS  PubMed  Google Scholar 

Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N. Engl. J. Med. 375, 1823–1833 (2016).

Article  CAS  PubMed  Google Scholar 

Robert, C. et al. Nivolumab in previously untreated melanoma withoutBRAFMutation. N. Engl. J. Med. 372, 320–330 (2015).

Article  CAS  PubMed  Google Scholar 

Sun, J. M. et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet 398, 759–771 (2021).

Article  CAS  PubMed  Google Scholar 

Rha, S. Y. et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 24, 1181–1195 (2023).

Article  CAS  PubMed  Google Scholar 

De Marchi, P. et al. PD-L1 expression by Tumor Proportion Score (TPS) and Combined Positive Score (CPS) are similar in non-small cell lung cancer (NSCLC). J. Clin. Pathol. 74, 735–740 (2021).

Article  PubMed  Google Scholar 

Burtness, B. et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394, 1915–1928 (2019).

Article  CAS  PubMed  Google Scholar 

Paz-Ares, L. et al. Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer. N. Engl. J. Med. 379, 2040–2051 (2018).

Article  CAS  PubMed  Google Scholar 

Ferris, R. L. et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 375, 1856–1867 (2016).

Article  PubMed  PubMed Central  Google Scholar 

Taube, J. M. et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. 20, 5064–5074 (2014).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thommen, D. S. & Schumacher, T. N. T cell dysfunction in cancer. Cancer Cell 33, 547–562 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fourcade, J. et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients. J. Exp. Med. 10, 2175–2186 (2010).

Article  Google Scholar 

Bevins, N. J. et al. Tumor infiltrating lymphocyte expression of PD-1 predicts response to Anti-PD-1/PD-L1 immunotherapy. J. Immunother. Precis Oncol. 5, 90–97 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Adashek, J. J. et al. LAG‐3 transcriptomic expression patterns across malignancies: implications for precision immunotherapeutics. Cancer Med. 12, 13155–13166 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Adashek, J. J. et al. Transcriptomic silencing as a potential mechanism of treatment resistance. JCI Insight. 5 https://doi.org/10.1172/jci.insight.134824 (2020).

Conroy, J. M. et al. Analytical validation of a next-generation sequencing assay to monitor immune responses in solid tumors. J. Mol. Diagn. 20, 95–109 (2018).

Article  CAS  PubMed  Google Scholar 

Jou, J. et al. Cancer immunity marker RNA expression levels across gynecologic cancers: implications for immunotherapy. Mol. Cancer Ther. 22, 1352–1362 (2023).

Goodman, A. M. et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol. Cancer Ther. 16, 2598–2608 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Overman, M. J., Ernstoff, M. S. & Morse, M. A. Where we stand with immunotherapy in colorectal cancer: deficient mismatch repair, proficient mismatch repair, and toxicity management. Am. Soc. Clin. Oncol. Educ. Book 38, 239–247 (2018).

Article  PubMed  Google Scholar 

Bear, A. S., Vonderheide, R. H. & O’Hara, M. H. Challenges and opportunities for pancreatic cancer immunotherapy. Cancer Cell 38, 788–802 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Miyashita, H. et al. T-cell priming transcriptomic markers: implications of immunome heterogeneity for precision immunotherapy. npj Genom. Med. 8, 19 (2023).

Fountzilas, E., Kurzrock, R., Vo, H. H. & Tsimberidou, A. M. Wedding of molecular alterations and immune checkpoint blockade: genomics as a matchmaker. J. Natl. Cancer Inst. 113, 1634–1647 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Yarchoan, M. et al. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insight 4, e126908 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Maule, J. G. et al. Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types. J. Immunother. Cancer 10, e005573 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Rimm, D. L. et al. A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non–small cell lung cancer. JAMA Oncol. 3, 1051 (2017).

Article  PubMed  PubMed Central  Google Scholar 

Tsao, M. S. et al. PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project. J. Thorac. Oncol. 13, 1302–1311 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Lee, J. S. & Ruppin, E. Multiomics prediction of response rates to therapies to inhibit programmed cell death 1 and programmed cell death 1 Ligand 1. JAMA Oncol. 5, 1614 (2019).

Article